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ABSTRACT
Objective: To estimate the incremental effect of waist circumference (WC)
on health-care costs among overweight and obese subjects after adjusting
for body mass index (BMI).
Methods: A prospective study. The subjects were members of Internet
panels in the United States (US) and Germany. 10,816 individuals (United
States: n = 5410; Germany: n = 5406) aged 30–70 years with BMI scores
between 20 and 35 kg/m2 were recruited and grouped by category: healthy
weight (BMI 20–24.9 kg/m2), overweight (BMI 25–29.9 kg/m2), and obese
(BMI 30–35 kg/m2). Within the overweight and obese categories, the
individuals were stratiﬁed by sex andwithin those subgroups, characterized
as above or below the median WC. The subjects self-reported weight, WC,
and health-care resource use at baseline, 3 months, and 6 months using
online questionnaires. Over 65% of the recruited subjects completed all
surveys. Resource utilization was translated into health-care costs by
multiplying unit costs from national sources in each country. Annualized
health costs were summarized for subjects with low and highWCwithin the
overweight and obese categories. A two-part model generated predicted
annual costs because of the WC difference controlling for BMI, demo-
graphic, and lifestyle variables among the overweight and obese subjects.
Results: When BMI and other characteristics are constant, annual health-
care costs are 16% to 18% higher in Germany and 20% to 30% higher in
the United States for the subjects with a high WC compared with subjects
with a low WC.
Conclusions: Targeting people with a high waist circumference for weight
management whether they are overweight or obese may maximize
cost-efﬁcacy.
Keywords: health-care costs, health conditions, obesity, waist circumfer-
ence.
Introduction
Obesity remains a critical and common health problem in the
United States. Numerous clinical studies have shown that obesity
is associated with increased mortality [1] and morbidity [2–5],
and decreased quality of life [6] as well as increased disability
[7,8] and increased health-care costs [9,10]. Although obesity is
usually deﬁned by measurements of body mass index (BMI) [11],
recently, it has been suggested that diseases may be associated
more with abdominal obesity (AO) than with BMI-deﬁned
obesity [12]. While links between AO and diabetes and coronary
heart disease risk are well established [13], the costs associated
with AO are less documented. Most large prospective studies
have evaluated the association between BMI, waist circumfer-
ence (WC), and health [13–16], but none of these studies have
explored the relationships with AO on health-care utilization and
costs. A large Danish cohort study reported an association
between high WC at baseline and subsequent health costs among
an older population [17]. Quantifying the impact of AO on
health-care costs would help reﬁne the evaluation of the burden
of obesity and may facilitate the effective targeting of interven-
tion. In addition, performing this research in both the United
States and one European country would provide a more infor-
mative result, independently of an individual health-care system.
In 2005, we conducted a pilot study of normal, overweight,
and obese individuals [18] to ascertain the effects of BMI and
AO/WC on diseases and health-care costs. The results suggested
a higher prevalence of diseases among those with higher WCs
within a particular BMI category and showed that subjects with
AO had higher resource use and costs compared to subjects
without AO [18]. However, results were mixed when the analy-
sis was reconsidered using WC categories based on AO cutpoints
(deﬁned by adult treatment panel [ATP] III or International Dia-
betes Federation [IDF]) within each category of BMI [19]. There-
fore, this full phase study was designed to examine the effect of
WC in the overweight and obese groups using cutpoints deter-
mined from the natural distribution of WC. Speciﬁcally, analyses
were designed to make comparisons within BMI categories by
WC subgroups by sex [i.e., overweight above and below the
median WC; obese above and below the median WC].
Hence, the objective of this study is to estimate the incremen-
tal effect of increasing WC on health-care costs for overweight
and obese patients with the same BMI (after adjustment for
patient-speciﬁc characteristics, such as lifestyle and demographic
factors), in both the United States and Germany.
Methods
Study Design
The PRospective Obesity Cohort of Economic Evaluation and
Determinants (PROCEED) Full Phase Study is a prospective
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cohort study in the United States and Germany that collected
self-reported health and health-care utilization data on normal
weight (20  BMI < 25 kg/m2), overweight (25  BMI < 30 kg/
m2), and obese (30  BMI  35 kg/m2) individuals followed up
for 6 months via the Internet. The BMI cutoff points were
selected based on well-established deﬁnitions for overweight and
obesity [20]. Within each BMI category, recruitment was further
stratiﬁed by sex to accomplish equal sex ratio (i.e., 50% males
and 50% females) within each BMI category.
Sample Size
The sample size was determined by formal sample size calcula-
tions, based on US pilot study data, accounting for expected
retention. A two-sided t test of costs would have 80% power to
detect a statistical difference if prescription costs are $141 higher
in the high WC subgroup than the low WC subgroup of the
overweight subjects (difference of $407 within the obese subjects)
assuming a common standard deviation ($1117) and alpha
(0.05). The normal weight group (control group) size was not
based on statistical considerations and was chosen to provide a
qualitative reference only.
Recruitment was stratiﬁed by BMI and sex to accomplish a
50% male–female ratio within each BMI category, such that each
country would include the following at baseline:
• 200 participants (100 males; 100 females) with
20  BMI < 25 kg/m2 (control);
• 4000 participants (2000 males; 2000 females) with
25  BMI < 30 kg/m2 (overweight);
• 1200 (600 males; 600 females) participants with 30 
BMI  35 kg/m2 (obese).
Data Collection
The study subjects were identiﬁed from existing large Web-based
research panels in the United States and Germany. The panel
members were Internet users who had voluntarily registered with
the panel. For this study, a random sample of existing panel
members who met the age, country, and participation criteria
were invited to participate via email. The email directed the
panelist to the online screening questionnaire to determine study
eligibility. The panelists were selected for inclusion if they met the
eligibility criteria: between the ages of 30 and 70 years (inclu-
sive); able to provide consent; had Internet access; able to read
English (US participants) or German (German participants);
weighed less than the scale limit of 130 kg (286 pounds); pro-
vided weight and WC measurements at screening and baseline;
had 20  BMI  35 kg/m2; and if female, were not pregnant.
The ﬂow of data collection is illustrated in Figure 1. As
quotas were met in each BMI category for each sex, recruitment
into that category was stopped. For the subjects who met the
inclusion criteria in the screening survey, scales and tape mea-
sures were provided at no cost to the participants within 2 weeks
of screening to standardize the tools used for weight and waist
measurement assessment. Then, these eligible subjects were sent
email invitations to participate in the baseline survey. Eligibility
was reconﬁrmed based on the weight and WC reported using the
study supplies. The eligible subjects completed the baseline
survey and two quarterly surveys.
Figure 1 Subject recruitment and retention. *Did not report country or reported a country other than the United States or Germany. †Panelists who completed
screening survey and met study criteria and consented to participate. ‡760 participants did not receive study supplies because supplies ran out (0.26% in the United
States and 0.35% in Germany). §Completers are subjects who completed all three assessments (baseline,month 3, and month 6). BMI, body mass index;Ger,Germany;
US, United States.
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To validate the body measurements, in-home visits were made
to a random subsample of the respondents using the same
approach as described in the PROCEED Pilot Study [18]. At
baseline, the overall difference between the self-reported and the
measured weight was <0.5 kg (correlations between 0.96 and
0.98) and 0.10 cm for WC (correlations between 0.87 and 0.88).
To ascertain the primary reasons for lost to follow-up, a survey
was conducted at the completion of the PROCEED 6-month
follow-up period. Those individuals who did not respond to the
month 6 survey were contacted by telephone and a brief interview
was conducted to collect information on health status, recent
resource use, and reason for discontinuation. A Web-based survey
was also offered for the respondents who did not have time for or
who were unwilling to participate in a telephone interview.
The participants received “points” equivalent to US$10 for
each completed assessment and the equivalent of US$5 “bonus”
points if they completed all the assessments. Points were redeem-
able for merchandise through the research panel.
The study was approved by RTI International’s institutional
review board and the German Ethics Committee of the Technical
University of Munich.
Outcome Measures
Key outcomes were health-care consumption including pharma-
ceutical use and inpatient and outpatient care. Health-care
resource use during the previous 3 months was assessed based on
self-reported responses to questions about hospitalizations
(number, length of stay, reason), emergency room or surgery
visits, health-care provider visits, outpatient procedures (surgery,
diagnostic, treatment, and laboratory), prescription medication
use, and rehabilitation care. Thus, the subjects who completed
the baseline questionnaire and follow-up surveys at months 3
and 6 provided data over a 9-month period.
Costing Methods
Health-care costs were derived by multiplying self-reported
resource use by unit costs. In the United States, unit costs were
derived from these sources.
• Inpatient costs: Healthcare Cost and Utilization Project
Nationwide Inpatient Sample [21] and Williams [22]. All
costs were converted to 2006 US dollars using the medical
consumer price index.
• Outpatient costs: Uniform Data System for Medical Reha-
bilitation [23], Medicare Physician Fee Schedule [24],
Resource-based Relative Value Scale [25], and the Florida
Agency for Health Care Administration [26].
• Prescription costs: Red Book [27]. Cancer medication costs
were not included.
German unit costs were derived from these sources:
• Statutory Health Insurance from ofﬁcial statistics for hos-
pitals (2005) [28];
• German Diagnosis Related Group system (2005) [28];
• Rehabilitation and average point value of outpatient
medical services (2005) [28];
• Medications paid by the Statutory Health Insurance (2005)
[28].
Costs were not included for the following: cancer, cold medi-
cations, and three medications unavailable in Germany; weight
loss and cosmetic outpatient surgeries; and consultations with
nonphysicians.
For the respondents who completed all the assessments, the
total costs were then annualized by multiplying 9-month costs by
a constant 1.33.
Statistical Methods
Analyses were performed on the subset of completers (i.e., sub-
jects who completed all the assessments including baseline,
month 3, and month 6). To assess the effect of WC on health-care
utilization costs within the BMI categories, the annualized total
health-care utilization costs and each cost component (inpatient,
outpatient, and prescription drug costs) were summarized for the
subjects in ﬁve mutually exclusive categories: 1) normal BMI; 2)
overweight with low WC; 3) overweight with high WC; 4) obese
with low WC; and 5) obese with high WC. The normal BMI
category provided a qualitative reference. Very few subjects with
normal BMI had AO. High WC and low WC were determined
based on sex-speciﬁc sample medians within each of the over-
weight and obese groups in each country (listed in Table 1), an
approach recommended by the advisory board of clinicians. The
sample median WCs were calculated using the baseline data for
the subjects who completed all the assessments.
To estimate the incremental effect of increasing WC on health-
care costs for the patients with the same BMI in the United States
and Germany, we implemented a two-part model [29,30] in each
country inwhich the probability of incurring health-care costswas
combined with the estimated cost of service. This analysis was
performed using the combined overweight and obese sample in
each country. In both parts of the model, same demographic and
lifestyle factors expected to be associated with health-care costs
were prespeciﬁed as covariates so that estimates of the effects of
WC and BMI on health-care costs are adjusted for these factors.
Besides BMI and WC (both as continuous variables), the covari-
ates included in the model were sex, age, race, education level,
health insurance, smoking status, alcohol consumption, and
medical conditions (depression and cancer). Separatemodels were
developed for prescription drug cost, outpatient costs, inpatient
costs, and total health-care utilization costs.
In part 1 of the two-part model, the probability that a subject
will use a health-care service (i.e., prob [Cost > 0]) over a 1-year
Table 1 Median waist circumference (in cm) by body mass index category and sex
Population
Normal BMI
20 BMI < 25
Overweight
25 BMI < 30
Obese
30 BMI 35
PROCEED
all
PROCEED
completers
National
survey
PROCEED
all
PROCEED
completers
National
survey
PROCEED
all
PROCEED
completers
National
survey
US NHANES NHANES NHANES
Males 90 90 89 100 100 100 112 112 111
Females 80 79 81 91 91 92 102 101 103
Germany GNHIS GNHIS GNHIS
Males 89 88 88 99 99 98 111 111 109
Females 79 79 76 90 90 87 101 101 98
BMI, body mass index; GNHIS, German National Health Examination and Interview Survey 1998; NHANES, National Health and Nutrition Examination Survey 2003–2004.
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period was estimated using a logistic regression model. Next, the
part 2 model was developed using only those patients who had
non-zero costs. An estimation of the expected annual costs was
generated using ordinary least squares regression against the set
of relevant covariates. Finally, expenditures for a population with
a given set of patient characteristics were estimated by multiply-
ing the probability of incurring the expense by the estimated cost.
Estimations were made at the midpoint BMI (27.5 in the
overweight group, 32.5 in the obese group) for a subject repre-
senting the 25th and 75th percentile of the sex-speciﬁc WC
distributions within the overweight and obese groups with all
other characteristics set to the average of the study sample in each
country. For the differences in costs between the high and low WC
groups, 95% conﬁdence intervals and P-values were calculated
using variances estimated by bootstrapping [31] from 1000 boot-
strapped samples. Analyses were generated using SAS software,
version 9.1 of the SAS System for Unix. Copyright © 2007 SAS
Institute Inc. SAS and all other SAS Institute Inc. product or service
names are registered trademarks or trademarks of SAS Institute
Inc., Cary, NC, USA (SAS Institute Inc., Cary, NC).
Role of the Funding Source
The study was conducted by RTI Health Solutions and Sanoﬁ-
aventis Recherche et Développement (S-A) and funded by S-A.
Results
Recruitment and Response Rates
Figure 1 illustrates the number of subjects completing each stage
of the recruitment process. In April 2007, email invitations were
sent out to a total of 412,981 panelists in the United States and
Germany, and 65,355 panelists responded to the invitation and
were screened. Of those screened, 16,077 were eligible and con-
sented to participate in the study. An additional 13,935 subjects
were qualiﬁed, but the recruiting quota had been met; data
collection ceased once enough participants were recruited to meet
the target sample sizes. In addition, 9387 subjects suspended (i.e.,
decided to stop before going through the survey questionnaire)
and 8711 subjects did not agree to participate in the study. The
remaining subjects (n = 17,245) were screened outmostly because
they were overweight, underweight, and did not report their
weight, height, or WC. Of the 16,077 that were eligible and
consented in the screening survey, a total of 10,816 responded to
the invitation to complete the baseline survey, were conﬁrmed as
eligible, and completed the baseline questionnaire (n = 5410 in the
United States; n = 5406 in Germany) after they received the study
scales and tape measures.
Of the baseline cohort, the response rate was 79% for the
3-month assessment and 72% for the 6-month assessment. Sixty-
eight percent in the United States (n = 3653) and 65% in
Germany (n = 3493) completed both follow-up surveys and are
included in the analyses.
Baseline Characteristics
Median WC values for the control/healthy, overweight, and
obese groups are shown in Table 1. The values were remarkably
similar across countries for each sex.
Table 2 show the demographic and baseline characteristics of
the US and German completers by BMI category and WC sub-
Table 2 Baseline demographic characteristics in the United States and Germany*
Normal
BMI (%)
Overweight
(BMI 25–29.9 km/m2)
Obese
(BMI 30–35 km/m2)
Gender speciﬁc median WC category (%) Gender speciﬁc median WC category (%)
WC median >WC median WC median >WC median
United States
Sample size 160 1374 1279 437 403
Mean age in years 49.2 48.9 52.0 51.1 51.8
30–39 (26) (24) (18) (16) (16)
40–49 (29) (34) (27) (28) (25)
50–59 (21) (20) (22) (33) (31)
60–70 (24) (22) (32) (23) (28)
Gender (% male) (56) (52) (53) (54) (53)
Race or ethnic origin (% Caucasian) (94) (92) (95) (95) (94)
Current smoker (30) (19) (23) (16) (26)
With alcohol intake (>1 drink/week) (49) (42) (40) (33) (33)
Education (at least one university degree) (49) (50) (42) (43) (36)
With health insurance coverage (93) (91) (91) (90) (88)
BMI: mean; SD 23.2; 1.3 27.1; 1.3 28.1; 1.2 31.6; 1.3 32.7; 1.4
WC: mean; SD 85.6; 9.5 89.6; 7 102.5; 7.1 101.3; 7.7 114.5; 6.7
Germany
Sample size 146 1326 1231 409 381
Mean age (in years) 43.2 44.3 47.9 45.4 47.9
30–39 (39) (34) (22) (29) (21)
40–49 (34) (38) (33) (41) (36)
50–59 (21) (20) (32) (23) (32)
60–70 (6) (7) (13) (8) (10)
Gender (% male) (51) (51) (53) (53) (54)
Race or ethnic origin (% Caucasian) (100) (99) (99) (99) (99)
Current smoker (52) (33) (36) (35) (46)
With alcohol intake (>1 drink/week) (50) (49) (47) (40) (40)
Education (at least one university degree) (36) (29) (26) (23) (21)
With health insurance coverage (97) (100) (99) (99) (98)
BMI: mean; SD 22.8; 1.3 27.0; 1.2 28.0; 1.3 31.7; 1.3 32.6; 1.5
WC: mean; SD 83.9; 8.6 89.7; 6.5 101.3; 6.2 100.4; 7.1 113.3; 6.8
*Based on subjects who completed surveys at 0, 3, and 6 months.
BMI, body mass index;WC, waist circumference.
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group. The mean age across the entire cohort was 48 years; in
both countries, more than 90% of the subjects were Caucasian.
Forty-ﬁve percent of the subjects in the United States and 27% of
the subjects in Germany reported having at least a university-
level education. About 91 % of the US subjects and 99% of the
German subjects reported having some form of health insurance.
In the overweight group, the low WC group is younger than the
high WC group. In both the overweight and obese groups, the
lower WC groups have a lower percentage of smokers and a
higher percentage with a university or higher degree. It is also
noteworthy that there is not much difference in mean BMI but a
large difference in mean WC. Our data suggested that only
30–50% of the variation in WC can be explained by BMI (results
not shown in the table). Baseline demographic characteristics and
prevalence of selected conditions were compared with noncom-
pleters and national survey data and are discussed later.
Health-Care Utilization and Costs
Over the entire study period, approximately 90% of the respon-
dents in both countries used at least one health-care service, thus
incurring a cost. Table 3 illustrate the annualized health-care
utilization costs for the United States and Germany by BMI
category and WC subgroup. In both countries, the pattern of use
indicated higher health-care utilization in the higher WC sub-
group compared with the lower WC subgroup in both the over-
weight and obese groups. A somewhat higher proportion of the
subjects incurred costs, and average costs were higher for the
subgroup with a higher WC compared with subjects in the low
WC subgroup for each BMI category. This observation was made
for total health-care costs and each cost component (inpatient,
outpatient, and prescription costs). The greatest differential was
observed in the proportion of subjects using prescriptions.
Predicted Annual Health-Care Costs
Figure 2 shows expected annual health-care costs based on US
subjects at prespeciﬁed BMI and WC, adjusted for age, sex,
education level, race, health insurance status, smoking status/
history, and alcohol consumption. For the subjects who are over-
weight or obese, expected prescription drug costs are
signiﬁcantly higher for the subjects above the median WC com-
pared with the subjects below the median. The overweight
females in the 75th percentile of the WC distribution (i.e., the
median of the high WC group) are predicted to generate $3096
in annual prescription costs versus $2430 for females in the 25th
percentile (i.e., the median of the low WC group) holding BMI
and other characteristics constant (P < 0.001). The overweight
males in the 75th percentile of WC are expected to have $2496
versus $1972 in annual prescription costs for males in the 25th
percentile (P < 0.001). Consistent differences across WC levels
were observed for the obese subjects (females: P < 0.001; males:
P < 0.001). Similar patterns were observed for inpatient costs
(overweight females: P = 0.042, overweight males: P = 0.037;
obese females: P = 0.045, obese males: P = 0.041). Outpatient
costs are expected to be higher for the overweight or the obese
subjects with higher WC compared with the subjects with WC
below the sample median, but predicted differences were not
statistically signiﬁcant at the P = 0.05 level (at BMI = 27.5 or at
BMI = 32.5: females P = 0.072; males P = 0.066). Total esti-
mated costs were signiﬁcantly higher for the overweight subjects
with high WC compared with the subjects with low WC (differ-
ence among females = $2394, P = 0.003; among males = $1923,
P = 0.002). The differences in predicted annual costs between the
obese subjects in the 75th versus the 25th percentile of the WC
distribution were $2418 for the females (P = 0.003) and $1970
for the males (P = 0.002). Ta
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In Germany (Fig. 3), all components of predicted health-care
costs were signiﬁcantly higher for the subjects above the median
WC compared with the subjects below the median both for the
overweight and the obese. Predicted annual prescription costs
were €516 for the females in the 75th percentile of WC and €445
for the females in the 25th percentile (P = 0.002), with BMI and
other characteristics held constant (for males: €423 vs. €366;
P < 0.001). The same pattern was found in the United States,
with absolute values greater in the obese than the overweight and
greater in the females than in the males. Differences in predicted
annual costs in the overweight subjects at the 75th versus 25th
percentile of the WC distribution were €393 for the females
(P = 0.005) and €316 for the males (P = 0.004). Among the obese
subjects, differences were €432 for the females and €358 for the
males (P = 0.005; P = 0.004).
In both countries, the subjects with a midpoint BMI of 27.5
whose WC was at the high end of the distribution among the
overweight subjects had a similar WC to the obese subjects with
a midpoint BMI of 32.5 whose WC distribution was at the low
end for that category. Furthermore, predicted health-care costs
were similar for these subjects with differing BMIs but similar
WCs.
Discussion
The goal of PROCEED was to determine the effect of WC on
health-care costs—in particular, prescription medication
costs—after adjusting for BMI and other potentially confounding
variables. When BMI and other characteristics are held constant,
annual health-care costs of the subjects with a high WC are 16%
to 18% (€300–€400) higher in Germany and 20% to 30%
($1900–$2400) higher in the United States compared with the
subjects with a lower WC. In the overweight and the obese
female and male subjects in Germany and the United States, a
higher WC was associated with signiﬁcantly higher total health-
care costs as well as inpatient, outpatient, and pharmaceutical
costs. The exception was outpatient costs among the overweight
subjects in the United States where the results approached but did
not reach statistical signiﬁcance (P = 0.07). These results conﬁrm
the importance of evaluating WC in addition to BMI and suggest
that targeting people with a high WC for weight manage-
ment whether they are overweight or obese may maximize
cost-efﬁcacy.
The higher health-care costs observed were reﬂections of the
higher disease prevalence among the subgroups with a higher
WC [32–34]. The association between high WC indicating AO,
and cardiovascular disease and insulin resistance is well estab-
lished [18,35–40]. Despite this known association, little is known
how or if this association translates into higher health-care uti-
lization and costs. Cornier and colleagues initially documented
the link between health-care costs and a high WC, but the popu-
lation was small (n = 424) and nongeneralizable (from one city in
the United States) [12]. More recently, ø´H jgaard and colleagues
reported, in a sample of 31,849 subjects aged 50–65 years and
residing in Denmark, that a high WC at baseline was associated
with increased health-care costs over a 7-year period [41]. Our
Figure 2 Predicted annual healt care costs in the
United States. Within the overweight and obese
groups, predictions were made at the BMI mid-
point (27.5 and 32.5, respectively) for the subjects
representing the 75th and 25th quartiles of the
sex-speciﬁc WC distributions. Other characteris-
tics were set to average for the United States
cohort: 21% 30–39 years, 31% 40–49 years, 23%
50–59 years, 25% 60–70 years; 93% Caucasian;
44% university degree or higher; 90% with health
insurance; 22% current, 33% former smoker; 40%
drinking 1 alcoholic beverage/week. P-values
correspond to the comparisons of costs between
high WC and low WC. Numbers in parentheses
represent 95% conﬁdence intervals. BMI,
body mass index; US, United States; WC, waist
circumference.
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study expands what is known about WC and health-care costs by
using a large population with a wider age range from two dif-
ferent countries, the United States and Germany. Thus, it pro-
vides insight that higher costs occur across all components of
health care.
One limitation of the current study is that the survey did not
collect the extensive details required to estimate the cost of
cancer treatments (e.g., stage of disease, type and line of therapy,
concurrent regimens). We note that cancer rates for the subjects
who completed the survey followed the same trend as for the
other conditions (i.e., higher cancer rates were seen in the above
median WC subgroups in the obese group in both countries and
the overweight group in the United States) (data not shown). We
surmise that the inclusion of drug costs for cancer would have
reinforced the patterns already observed but may have skewed
the overall results with extreme cost values.
Another limitation of the current study is that the participants
had to have Internet access. The advantage and validity of Inter-
net recruitment and data collection methods have been docu-
mented in previous studies [33,42]. The current study sample
was compared with data from available national probability-
based surveys for each BMI group in each country using the US
2003–2004 National Health and Nutrition Examination Survey
[43] and the 1998 German National Health Examination and
Interview Survey (GNHIS) [44]. The US PROCEED cohort is
very similar to the National Health and Nutrition Examination
Survey (NHANES) cohort with regard to most demographic
characteristics (i.e., education level, marital status, and income
level) and selected health and behavioral characteristics (i.e.,
hypertension, high cholesterol, diabetes, and smoking), except
for higher proportion of White subjects and a slightly higher
mean age in the PROCEED cohort than in the NHANES
cohort (by 3.1 years in the normal weight group, 1.6 years in
the overweight group, and 3.6 years in the obese group). The
German PROCEED cohort, on average, is younger than the
GNHIS cohort (1.6 years mean difference in normal weight
group, 4.2 years in overweight group, and 5.2 years in obese
group), has a higher proportion (>10% point difference) of par-
ticipants with higher education (“abitur” in German), and has a
higher proportion of single participants. The percentage with an
apprenticeship (“lehre” in German) is similar in PROCEED and
the GNHIS. Percentages of hypertension, high cholesterol, and
diabetes are very similar to GNHIS data. Despite differences in
some characteristics, the PROCEED cohort is generally compa-
rable to the US and German general populations. In addition, it
is important to realize that the PROCEED sample contains a
sufﬁcient range of key demographics, such as age, race, and
education level, so that statistical models can be developed to
account for these characteristics.
The use of distribution-based WC cutpoints may also lessen
the generalizability of these results to other populations.
However, within the normal, overweight, and obese groups of
the PROCEED cohort, the distribution of WC values are com-
parable with national survey data in the United States and in
Germany. Observed WC measures in this naturalistic cohort
were similar between countries and may be useful to describe the
Figure 3 Predicted annual health care costs in
Germany. Within the overweight and obese
groups, predictions were made at the BMI mid-
point (27.5 and 32.5, respectively) for the subjects
representing the 75th and 25th quartiles of the
sex-speciﬁc WC distributions. Other characteris-
tics were set to average for the German cohort:
31% 30–39 years, 36% 40–49 years, 24% 50–59
years, 9% 60–70 years; 98% Caucasian; 25% univer-
sity degree or higher; 99% with health insurance;
38% current, 29% former smoker; 45% drink-
ing 1 alcoholic beverage/week. P-values corre-
spond to the comparisons of costs between high
WC and low WC. Numbers in parentheses rep-
resent 95% conﬁdence intervals. BMI, body mass
index;WC, waist circumference.
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relationship between actual WC measures and health-care
resource use and cost. We noted that the median WC values in
the overweight females were higher than the ATP III criteria for
AO and lower in the overweight males.
The cost analysis was performed on the subset of completers,
which means the subjects who completed the baseline and
months 3 and 6 surveys. Among the baseline participants, 68%
in the United States and 65% in Germany completed all the
assessments and were included in analysis. The baseline demo-
graphic characteristics (i.e., sex, age, education, income, and
employment status) and prevalence of selected conditions (i.e.,
hypertension, dyslipidemia, diabetes, depression, coronary heart
disease, and cancer) were compared for the completers against
the noncompleters in each BMI category and country. No
difference was consistently found across the BMI groups or the
countries.
In addition, a lost-to-follow-up survey was conducted to
ascertain the reason for nonresponse. Approximately 10% to
15% of the noncompleters did not complete the follow-up survey
because they discontinued from the Web panel. Approximately
20% to 30% of the nonresponders answered one or a few
questions in the follow-up survey but did not ﬁnish all questions.
Over 30% of the nonresponders completed the lost-to-follow-up
survey. The most prevalent reasons cited for not completing the
PROCEED survey in both the United States and Germany was
that the subject became too busy or did not have time (37% and
45%, respectively). Eleven percent of the US and 16% of the
German cohorts reported being hospitalized in the past 12
months, which is comparable with the completers.
It is now well established that obesity is a heterogeneous
condition and that not every overweight/obese individual is at
high risk of complications. The present study adds further evi-
dence that at any given BMI value, individuals with an elevated
WC have greater health-care costs. Although experimental data
will be needed to test this hypothesis, given scarce health-care
resources and the fact that more than half of the population in
industrialized countries are overweight and obese, it is reason-
able to suggest that the subgroup of overweight/obese individuals
with a high WC may beneﬁt the most from approaches that aim
at weight loss and loss of abdominal fat. Of course, intervention
studies are needed to speciﬁcally examine this issue.
Source of ﬁnancial support: Sanoﬁ-aventis Recherche et Development.
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